("4basebio" or the "Company")
Director Dealing
Cambridge, UK, 16 February 2026
– 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on
Further details are set out in the Notification of Dealing Form below.
Shareholding
Shareholding Following
Director / PCA Number of Ordinary Purchase Price Following Acquisition as a
Shares Acquired (Aggregated) (p) Acquisition Percentage of
Issued Share
Capital
Dr. Amy Walker 2,650 586.08 46,666 0.30%
The 2,650 shares purchased represent approximately 0.02 per cent. of the Company's issued share capital.
The issued share capital of the Company comprises 15,538,518 ordinary shares.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.
For further enquiries, please contact:
4basebio PLC +44 (0)12 2396 7943
Dr Amy Walker , CEO
Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes
Cavendish Capital Markets Limited (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Nigel Birks RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Kathryn Deegan / Matthew Coakes ICR Healthcare (Media and Investor Relations) +44 (0)203 707 5700
Mary-Jane Elliott / Jessica Hodgson
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
Forward-looking statements
This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the persons discharging managerial responsibilities / person closely associated a)Name Dr.Amy Walker 2 Reason for the notification a) Position/Status Chief Executive Officer b) Initial notification/ Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a)Name 4basebio plc b) LEI 213800E2DX9EAIUNCB30 Details of the transaction(s): section to be repeated for (i) each type of 4 instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted Description of the financialinstrument, type Ordinary Shares a) ofinstrumentIdentification code ISIN: GB00BMCLYF79 b) Nature of the transaction Acquisition of ordinary shares Price(s) Volume(s) c) Price(s) and volume(s) 586.08p 2,650 d) Aggregated information- Aggregated volume- 2,650586.08p Aggregated Price e) Date of transaction13 February 2026 f) Place of transactionLondon Stock Exchange
